University of Kansas Medical Center
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-IMRT/durvalumab. A modest improvement in locoregional control (LRC) was selected as a target which could merit further study of this hypofractionated IMRT regimen in a Phase III trial
Inclusion Criteria: * Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent * Males and females age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2 * Measurable disease by RECIST 1.1 * Women of childbearing potential must have a negative serum pregnancy test within one month prior to initiating treatment * Pathologically proven diagnosis of Stage IIIA or IIIB non-small cell lung cancer (NSCLC) * No Positron Emission Tomography (PET)/CT evidence of metasta…
62.5 Gy in 25 fractions of 2.5 Gy/fraction
60 Gy in 30 fractions of 2 Gy/fraction